Raffles Associates LP increased its stake in shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX – Free Report) by 35.8% in the second quarter, Holdings Channel.com reports. The institutional investor owned 4,357,781 shares of the company’s stock after acquiring an additional 1,147,800 shares during the period. Lineage Cell Therapeutics makes up about 4.9% of Raffles Associates LP’s holdings, making the stock its 8th largest holding. Raffles Associates LP’s holdings in Lineage Cell Therapeutics were worth $4,346,000 at the end of the most recent reporting period.
Other large investors have also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD boosted its position in shares of Lineage Cell Therapeutics by 77.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 161,314 shares of the company’s stock worth $239,000 after buying an additional 70,418 shares during the period. Comerica Bank grew its stake in shares of Lineage Cell Therapeutics by 84,745.8% in the first quarter. Comerica Bank now owns 250,295 shares of the company’s stock worth $370,000 after purchasing an additional 250,000 shares in the last quarter. Fifth Third Wealth Advisors LLC acquired a new position in shares of Lineage Cell Therapeutics during the first quarter valued at $30,000. DCF Advisers LLC lifted its holdings in Lineage Cell Therapeutics by 14.5% in the fourth quarter. DCF Advisers LLC now owns 94,751 shares of the company’s stock worth $103,000 after purchasing an additional 12,000 shares during the period. Finally, XTX Topco Ltd bought a new position in Lineage Cell Therapeutics in the 2nd quarter valued at about $61,000. 62.47% of the stock is owned by institutional investors and hedge funds.
Lineage Cell Therapeutics Stock Performance
LCTX opened at $0.94 on Tuesday. The firm has a market capitalization of $178.04 million, a PE ratio of -6.73 and a beta of 1.26. Lineage Cell Therapeutics, Inc. has a one year low of $0.77 and a one year high of $1.61.
Analyst Ratings Changes
Separately, Craig Hallum assumed coverage on shares of Lineage Cell Therapeutics in a research note on Tuesday, August 20th. They issued a “buy” rating and a $4.00 price target for the company.
Read Our Latest Research Report on LCTX
Lineage Cell Therapeutics Profile
Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.
Featured Articles
- Five stocks we like better than Lineage Cell Therapeutics
- What is a Bond Market Holiday? How to Invest and Trade
- Seize the Growth: Twilio’s AI Innovations Are Driving Huge Upside
- ETF Screener: Uses and Step-by-Step Guide
- Rate Cut Shockwaves: Which Bank Stocks Will Rise or Fall?
- Find and Profitably Trade Stocks at 52-Week Lows
- S&P 500 Shake-Up: New Entrants Driving Market Momentum
Want to see what other hedge funds are holding LCTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX – Free Report).
Receive News & Ratings for Lineage Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lineage Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.